Repetitive sequences that shape the human transcriptome  by Jasinska, Anna & Krzyzosiak, Wlodzimierz J.
FEBS Letters 567 (2004) 136–141 FEBS 28367Minireview
Repetitive sequences that shape the human transcriptomeAnna Jasinska, Wlodzimierz J. Krzyzosiak*
Institute of Bioorganic Chemistry, Laboratory of Cancer Genetics, Polish Academy of Sciences, Noskowskiego 12/14 St., 61-704 Poznan, Poland
Received 29 February 2004; accepted 7 March 2004
Available online 22 April 2004
Edited by Horst FeldmannAbstract Only a small portion of the total RNA transcribed in
human cells becomes mature mRNA and constitutes the human
transcriptome, which is context-dependent and varies with
development, physiology and pathology. A small fraction of
diﬀerent repetitive sequences, which make up more than half of
the human genome, is retained in mature transcripts and shapes
their function. Among them are short interspersed elements
(SINEs), of which Alu sequences are most frequent, and simple
sequence repeats, which come in many varieties. In this review,
we have focused on the structural and functional role of Alu
elements and trinucleotide repeats in transcripts.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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A predominant part of the human genome consists of re-
petitive sequences of various types encompassing large seg-
mental duplications, interspersed transposon-derived repeats
and tandem repeats [1]. The latter include satellites, minisat-
ellites and microsatellites known also as simple sequence re-
peats (SSRs). In contrast, the coding sequences of the nearly
25 000 human genes comprise about 1% of the genome, and
about the same genome share can be assigned to their regu-
latory sequences (Fig. 1). This distinction between the repeti-
tive and coding/regulatory sequences does not necessarily
mean that these sequences are physically separated from each
other in the genome. It often happens, that some of these re-
peats occur within genes and even within their coding se-
quences and perform regulatory functions. It also happens that
the repeats increase the likelihood of deleterious mutations in
their host genes, thus increasing the risk of disease.
The human genome is basically uniform and only about 0.3%
of its sequence diﬀers between individuals in a population.
However, genetic information is the source of much higher
diversity observed at the transcriptome level. The term tran-
scriptome is young and its ﬁrst appearance was in 1997 to de-
scribe the set of genes expressed from the yeast genome [2].
According to a more recent deﬁnition the term stands for the
complete collection of transcribed elements of the genome [3].* Corrsponding author. Fax: +48-61-8520532.
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doi:10.1016/j.febslet.2004.03.109In addition to mRNAs, it also includes various non-coding
RNAs playing either structural or regulatory functions in cells.
Hence, there are thousands of diﬀerent transcriptomes in
hundreds of diﬀerent cell types and organs in their various
physiological and pathological states. The variety of transcripts
as compared to genes increases by about 50% due to alternative
splicing [4,5], the numerous antisense transcripts are synthe-
sized [6], and all non-protein-coding RNAs [7,8] including the
recently recognized microRNA family [9] also make a signiﬁ-
cant contribution to the pool of human transcripts.
It has been known for some time that human mRNAs
comprise about 2–3% of cellular RNA and they may be
characterized as belonging to diﬀerent abundance classes. A
small number of mRNAs are synthesized in several thousands
of copies, others occur in hundreds of copies, and the majority
is present in less than ten copies per cell [10]. Altogether, as
many as 500.000 mRNA molecules may exist in a single hu-
man cell. They are usually the products of about 25–50%
human genes expressed in most tissues and cell types. Only in
brain tissue is the number of expressed genes much higher. The
above numbers give some impression of the complexity of the
transcriptome, and show that its nearly complete character-
ization, as with the human genome sequence, may be an
enormous task [3].2. Alu sequences in human transcripts
Nearly half of the human genome derives from transposable
elements (TEs) which are abundant in gene sequences and are
also present in a signiﬁcant portion of mature mRNAs, mostly
in their untranslated regions [11]. Various TEs: the LTR, Alu,
L1 and MIR sequences inﬂuence gene regulation at the level of
transcription, e.g., by providing alternative promoters to many
genes. Interestingly, the TEs are more prevalent within the
mRNAs of the recently expanded gene families, which implies
their role in genome evolution [12].
Among diﬀerent TEs, the primate-speciﬁc Alu sequences are
the most abundant and their 1.1 million copies account for
more than 10% of the human genome [1]. They belong to ﬁve
major subfamilies diﬀering in the age of their appearance dur-
ing hominoid evolution and have speciﬁc diagnostic diﬀerences
in their sequences [13,14]. The oldest Alu sequences of the Alu-
Jo and Alu-Jb elements are estimated to be 65–80 million years
old, and the youngest Alu-Y class is about 15 million years old.
The most abundant in the genome is the 30–50 million years old
Alu S subfamily and in particular its Alu-Sx member. Theblished by Elsevier B.V. All rights reserved.
Fig. 1. Composition of the human genome. The percentage shares of various functional and non-functional sequences are shown.
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about 280 nucleotides and their structure composed of two
unequal monomer units [13,14].
The Alu sequences may change the genome in several dif-
ferent ways including insertion mutagenesis, gene conversion
and recombination between the repeats [15]. They are also
known as the genome-wide modiﬁers of gene expression. This
can be achieved either by disrupting promoters, changing their
methylation status or by inserting new regulatory signals, e.g.,
binding sites for steroid hormone receptors [16]. They may also
shape human transcriptome by interfering with the splicing
process. Harboring the motifs in their nucleotide sequences
that resemble the splice sites, they can mimic exons and be-
come a part of mature mRNAs [17]. As most of the Alu in-
sertions to protein coding regions are deleterious to cells, the
internal exons containing Alu sequences are often alternatively
spliced, and selected against [18]. The Alu sequences may also
create genetic novelties being a rich source of raw material for
experiments carried out by the evolution [19].
The extreme example of the Alu-rich gene is BRCA1 in-
volved in the hereditary predisposition to breast and ovarian
cancer. As much as 40% of its 80 kb genomic sequence is
composed of Alu sequences [20]. The Alu elements occurring
in various BRCA1 introns were reported to cause numerous
complex changes in the genomic, sequence which were asso-
ciated with the increased risk of these cancers [21]. A number
of other hereditary human diseases, e.g., hemophilia, have also
been attributed to Alu insertions in the implicated genes, and
more disorders including hypercholesterolemia, a-thalassemia
and thromboﬁlia were caused by the Alu/Alu recombination
[22]. These examples show that Alu sequences may be involved
in diseases not only through their high content but also due to
their speciﬁc locations within gene sequences.
Importantly, the Alu elements that occur in mRNAs may
also inﬂuence their translation [23]. When Alu occurs in a
leader sequence of mRNA, it may regulate the initiation step
of translation. This is the case of the BRCA1 mRNA which
has two forms diﬀering in their leader sequences and patterns
of expression [24]. The mRNA containing a shorter leader is
expressed in normal mammary tissue, whereas the one with a
longer leader containing the Alu sequence is expressed inbreast cancer tissue. We have shown that mRNA with the
longer 50-UTR is translated with 10 times lower eﬃciency and
that the stable structure formed by the Alu element is the
major factor responsible for this eﬀect [25]. Thus, the Alu-
mediated BRCA1 downregulation in sporadic breast cancer
may be considered the eﬀect equivalent to the gene mutation in
hereditary cancer, which contributes to the decrease of BRCA1
protein in the tumor tissue. It is worth noting, that the Alu
insert present in the BRCA1 leader is 60 nt shorter than the full
length Alu, but its right monomer that forms the stable
structure hampering the ribosome scanning is basically intact.
Our transcriptome-wide survey performed with bioinformatic
tools revealed that about 4% of human mRNAs harbor Alu
elements and those containing intact right monomers in their
leaders may exploit the same regulatory mechanism [25].3. SSRs in the human genome
The SSRs known also as short tandem repeats or microsat-
ellites are deﬁned as tandemly repeated tracts of DNA com-
posed of 1–6 base pair long motifs. The number of repeats in a
tract is usually less than ten and if it is higher the repeat length
polymorphism is often observed [26]. In rare cases, the repeat
number may reach hundreds and even thousands. All SSRs
taken together occupy about 3% of the human genome in which
they are widely dispersed and associated with many genes [27].
The genomic distribution of the SSRs of diﬀerent motif lengths
and sequences is strongly biased. With the exception of the
most prevalent SSRs composed of monomeric motifs, the
classes of repeated dimers, tetramers and hexamers, which
show nearly equal density in the genome, are 3–4 times more
abundant than those of trimers and pentamers [28]. When the
occurrence of SSRs in diﬀerent functional genome regions is
considered, it turns out that most of them show much higher
density in non-coding regions. Exceptions to the rule are tri-
mers and hexamers which are nearly two times more prevalent
in exons compared to introns and intergenic regions [28,29].
Their high frequency in coding regions may be explained by the
fact that they do not change the reading frames and gene coding
properties and, thus, are much better tolerated than other
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function for the repeats. This, however, remains barely known
despite the fact that the properties of trinucleotide repeats have
been extensively studied over the past decade. The high muta-
tion rate of these repeats and their frequent length polymor-
phism have raised speculations that they may be involved in the
regulation or ‘‘ﬁne tuning’’ of gene expression and function,
and have quantitative eﬀects on phenotype [30].4. Trinucleotide repeats in the human transcriptome
Focusing now on triplet repeats in the human transcriptome,
we have recently asked the questions: how many diﬀerent
mRNAs harbor such repeats in their sequences? At what fre-
quencies do certain types of repeats occur? And, what are the
preferred repeat locations in mRNAs? To answer these ques-
tions, the GenBank database was trawled for all 20 diﬀerent
triplet repeat tracts composed of at least six repeats, and the 718
repeat tracts were found in 619 mRNAs [31]. Most of the
identiﬁed mRNAs (87%) carried short repeat tracts 6–10, those
harboring 11–20 repeats contributed 11%, and those containing
more than 20 repeats – only 2% to the total. The most fre-
quently occurring repeated motifs were CAG, CGG, CCG,
CUG, AGG and ACC, whereas the ACG, AUC, CUU, AGU,
CGU and ACU were very poorly represented. Considering
diﬀerent mRNA regions, most of the repeats were located in the
ORF (67%), followed by 50-UTR (24%) and 30-UTR (9%). The
GC-rich repeats were more prevalent in the 50-UTR, whereas
the AU-rich were more abundant in the 30-UTR. Taking into
account length diﬀerences between the mRNA untranslated
regions, the repeats were strongly over-represented in mRNA
leaders implying their role in translation regulation [31].5. CNG repeats form hairpin structures in transcripts
As the ﬁrst step in searching for any biological functions of
trinucleotide repeats in transcripts, we performed a systematic
structure analysis using a battery of chemical and enzymatic
probes. These experiments, besides answering important ques-
tions concerning the structure formation abilities of diﬀerent
repeats ([32], unpublished data), provided unique information
regarding the speciﬁcity of diﬀerent structure probes acting on
highly regular RNA sequences. Out of the investigated 20
model transcripts composed of all possible triplet repeat motifs
reiterated 17 times, 6 transcripts were shown to form hairpin
structures. Among themwere all the CNG repeats shown by our
bioinformatic analysis to be the most abundant in transcripts
[31]. The quasistable hairpin stem structure is composed of the
periodically occurring C–G, G–C pairs and N–N mismatches,
and the repeats show a tendency to assume several variantive
alignments if this process is not suppressed by the presence of a
suitable GC clamp [32]. The characteristic feature of hairpins
formed by the CNG repeats is that their structure rigidity in-
creases with repeat length. For example, hairpin formed by the
(CUG)49 has a stem structure which shows a melting temper-
ature much higher than that of (CUG)21 and is completely
resistant to the single strand speciﬁc probes [33]. Moreover, the
long CUG and CAG hairpins behave as regular double-stran-
ded RNA structures with typical RNA-A geometry [34].It is known that the long double-stranded RNAs are toxic to
human cells possibly due to their non-speciﬁc eﬀects on gene
expression [35]. They are likely to induce the interferon (IFN-
a=b)-related pathways stimulating apoptosis and activate the
20,50-oligoA synthetase/RNaseL enzymes resulting in RNA
degradation. The long dsRNAs activate also the RNA-de-
pendent protein kinase (PKR)-mediated antiviral responses
including the general inhibition of translation and induction of
cell death [35]. In this context it is interesting to note that the
CAG and CUG repeat hairpins were reported to activate PKR
[36,37], whereas the CGG hairpin was shown to be inactive
[38]. The double-stranded RNAs can also induce RNA inter-
ference (RNAi), which is a sequence speciﬁc RNA degradation
mechanism developed to combat viral RNA, operating in
many organisms including humans [39]. The ribonuclease Di-
cer, which cuts the dsDNA into about 22nt long RNA du-
plexes, was recently shown to cut the long CGG repeat
hairpins also [38]. According to our experience, all types of the
CNG repeat hairpins are Dicer substrates if they are long
enough (unpublished data).6. Mechanism of pathogenesis in triplet repeat expansion
diseases
The pathways described above in which the long dsRNAs
execute their toxic eﬀects in cells are not the only ones. There is
also another mechanism of RNA pathogenesis mediated by
SSRs. Before discussing its various aspects, we provide some
background in brief. In 20 human genes the polymorphic re-
peats, in most cases triplet repeats of the CNG type, undergo
pathogenic expansions that cause hereditary human neuro-
logical diseases, the so called triplet repeat expansion diseases
(TREDs) [40]. The best known examples of these diseases are:
myotonic dystrophy, fragile X syndrome, Huntington disease
and a number of spinocerebellar ataxias. The expandable re-
peats are present in all parts of the implicated genes, mostly in
their ORFs but also in 50-UTRs, 30-UTRs and introns as
shown schematically in Fig. 2. In the majority of the disease-
related genes containing the CAG repeats in their coding se-
quences, the pathological repeat number begins at about 40
and may reach 100. On the contrary, the expansions of repeats
located in non-coding regions are usually larger and more
variable. The repeats present in the translated regions are
thought to exert their pathogenic functions on the level of
proteins which in most cases contain expanded polyglutamine
tracts [41]. Transcripts with the expanded repeats present in
non-coding regions, as they do not give rise to aberrant pro-
teins, may be transcriptionally silenced or translationally in-
hibited as in the fragile-X-syndrome or tremor ataxia
syndrome, respectively [42]. In both disorders the FMR1 gene
is implicated. They may also activate some other RNA-medi-
ated mechanisms like that of the speciﬁc protein sequestration
postulated for myotonic dystrophies type 1 and type 2 (in-
volving the DMPK and ZNF1 genes, respectively) [43].
The originally proposed mechanism of RNA pathogenesis in
myotonic dystrophy implied that long CUG repeats conﬁscate
speciﬁc repeat binding proteins from their normal binding sites
in other transcripts and compromise their function [44]. We
have shown that such repeats form stable hairpins, thus the
sequestered proteins must be the dsCUG repeat binding pro-
teins [33]. Such proteins were then isolated [45] and shown to
Fig. 2. Location of expandable repeats in the genes involved in repeat expansion diseases. The disorders for which the involved genes and transcripts
were subjected to detailed studies in our laboratory are highlighted with a yellow background.
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48]. More recently, the muscleblind knockout mouse model for
myotonic dystrophy revealed that the lack of this protein leads
indeed to abnormalities characteristic for the disease in hu-
mans [49]. In this way the protein sequestration mechanism
was further supported. Interestingly, the CUG repeat expan-
sion also causes the up-regulation of the single-stranded CUG
repeat binding proteins (CELF), which results in the altered
expression of several target genes [50].7. Uniﬁed model of RNA-mediated pathogenesis in TREDs
The question whether a similar RNA-mediated mechanism
of pathogenesis may operate also in other TREDs was recently
addressed by several authors. Not only the diseases caused by
the repeat expansions in non-coding sequences [42,51] but also
the so-called polyglutamine diseases were considered in this
context [31,32,52]. We have shown that at least the RNA
hairpin structures, which are behind the RNA pathogenesis in
myotonic dystrophy have the same architecture also in other
TREDs-related transcripts [32,33]. Thus, they have the po-
tential to interact with the speciﬁc dsRNA binding proteins. In
line with that, the dsCAG repeat binding proteins were de-
scribed [53] and identiﬁcation of the dsCGG repeat binding
protein was reported [54].
It has been argued by the proponents of the more prominent
role of RNA in pathogenesis of TREDs that the toxic eﬀect of
the expanded polyglutamine containing proteins may not be
the only mechanism of toxicity and may not be the one re-
sponsible for neuronal dysfunction [52]. Indeed, the polyglu-
tamine protein aggregation was shown to be neither necessary
nor suﬃcient for neurodegeneration [41]. Among other argu-
ments were the facts that most TREDs show dominant in-
heritance independent of the localization of mutation, and that
SCA8 is characterized by similar clinical phenotype as other
spinocerebellar ataxias despite the fact that SCA8 RNA is a
non-coding antisense transcript containing expanded CUG
repeat [52]. Thus, the common molecular feature of these
diseases independent of the position of the repeat expansioncould be the presence of expanded transcripts in the nucleus, in
some diseases also in cytoplasm, in most cases in the form of
long stable hairpin structures.
According to the hypothesis which was put forward recently
[31], not only the expanded repeat hairpins but also the over-
expressed transcripts containing long repeats (still within
normal length range) could either trigger pathogenesis or at
least modulate the pathogenic eﬀect. This hypothesis was
rooted in the observation that not only the expanded CUG
repeat hairpin but also the much shorter one (CUG)20 showed
a considerable binding of the muscleblind protein [45]. From
the perspective of the agent triggering pathogenesis, two fac-
tors are important for the protein sequestration mechanism:
the suitable structure and suﬃcient length of the repeat hairpin
stem, and the copy number of its harboring transcript per cell.
This is so because the number of eﬀective protein binding sites
is the factor which matters.
In support of this hypothesis and the uniﬁed model for RNA
pathogenesis in TREDs, there are recent results showing RNA-
mediated neurodegeneration caused by the FMR1 permutation
[55]. The hairpin structure formed by the CGG repeats in the
FMR1 transcript [38,56] together with its 5–10-fold increased
level [57] likely to activate RNA pathogenesis in permutation
carriers [55]. The resulting syndromes, tremor-ataxia and pre-
mature ovarian failure, diﬀer signiﬁcantly in their clinical fea-
tures from the fragile X syndrome developed in full mutation
carriers [57]. The FMR1 example shows that two diﬀerent
mechanisms of pathogenesis may be triggered depending on the
diﬀerent number of repeats within the same gene.8. Other factors relevant to protein sequestration mechanism
The mechanism of RNA pathogenesis has to be considered
also from the perspective of transcripts depleted from the
proteins they normally bind and having their normal functions
impaired. A group of such transcripts has been preliminarily
selected using bioinformatic methods [31]. The diﬃculty with
their selection is that the status of their repeat length poly-
morphism is known for about 10% of the identiﬁed repeat
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determine their normal repeat length ranges and stable hairpin
structure formation abilities.
Our initial sampling of the 10 TREDs-related genes (20 al-
leles) showed that the number of long alleles (containing more
than 20 repeats) ranged from 1 to 8 in genomes of the inves-
tigated individuals [Jasinska et al. submitted]. This result
shows that the genetic background in which the expanded re-
peat exerts its pathogenic eﬀect may vary signiﬁcantly between
individuals in a population. However, for the mechanism of
RNA pathogenesis in TREDs the transcriptome background is
more relevant than that of the genome. Therefore, the ex-
pression patterns and levels of the repeat containing transcripts
need to be determined in cells and tissues which are aﬀected by
the diseases and in those unaﬀected as well. This knowledge,
which is being gathered now, is required because not only the
presence or absence of the speciﬁc transcripts but also their
abundance in a given cell type may be important.
As the structures formed by the repeats alone and by the
repeats in their host transcripts may diﬀer, it was necessary to
ﬁnd out what is the architecture of the repeat regions within
their natural sequence context. This problem was also impor-
tant from the perspective of the cellular function of normal
length repeats as well as from that of the putative role of long
normal repeats in pathogenesis. According to structure pre-
diction, in a number of TREDs-related transcripts: the FMR2,
AR, SCA6, SCA7 and SCA12 repeat ﬂanking sequences con-
tribute signiﬁcantly to the stability of the repeat hairpins [31].
For most of these transcripts, these predictions were experi-
mentally conﬁrmed ([56], Michlewski and Krzyzosiak, sub-
mitted). In several other studied TREDs-related transcripts,
the repeats have more freedom of alignment and form a
number of slipped hairpin variants ([33], unpublished data). If
the uniﬁed RNA-mediated mechanism of pathogenesis indeed
operates in cells of TREDs patients, the various contributions
from ﬂanking sequences may play the role of co-factors in-
volved in determining diﬀerent pathogenic repeat length
thresholds in diﬀerent diseases.9. Structural role of repeat interruptions in transcripts
In three out of the 20 TREDs-related genes: the SCA1,
SCA2 and FMR1, their normal variants contain speciﬁc in-
terruptions in the repeat tracts, and these interruptions are
absent in the expanded mutant alleles. The repeat expansions
are thought to occur predominantly as the result of DNA
slippage during replication and the loss of interruptions was
postulated either to precede or to follow the repeat expansion
[58]. As a result of a comprehensive genotyping study, the
patterns of repeat interruptions in the SCA1 and SCA2
were determined for the Polish population and their relevance
to the repeat expansion mechanism and disease incidence was
discussed [58].
The presence of interruptions in the repeated sequence ob-
served in some genes is the cellular strategy which prevents
repeat expansions in DNA. To characterize the normal func-
tions of the repeats in RNA, the roles played by the repeat
interruptions have to be established. This has been done for the
transcripts of all three implicated genes using chemical and
biochemical methods [Napierala et al. submitted, Sobczak and
Krzyzosiak submitted]. In the case of the SCA1 RNA, thestructures of representative alleles containing either one, two or
three CAU interruptions present at diﬀerent localizations
within the repeat tract were analyzed. It turned out that, that
the interruptions either enlarge the terminal loop of the hairpin
formed by the CAG repeats, nucleate internal loops in the
hairpin stem, or force the repeats to form two smaller hairpin
structures. Thus, their role in RNA is to destabilize the repeat
hairpin structure, most likely to decrease its ability to interact
with dsCAG repeat binding proteins and participate in the
putative RNA pathogenesis mechanism [Sobczak and Krzyz-
osiak, submitted]. A similar role can be assigned to repeat in-
terruptions in the SCA2 and FMR1 transcripts, although
several details of structure destabilization strategy are diﬀerent.10. Concluding remarks
In this article, we have shown the variety of ways in which
just two diﬀerent classes of human repetitive sequences may
inﬂuence gene expression and function at the level of tran-
scripts. In the case of Alu sequences, it turns out that the in-
sertion site matters as well as the size and nature of the inserted
fragment. All these factors may be important for the eﬀects
that Alu elements generate and these eﬀects may range from
modulatory to deleterious. In the case of triplet repeats, it is
their length variation and localization within a transcript
which determine their variable eﬀects on phenotype, and may
decide which mechanism of the pathogenesis is activated. As
the ﬁeld develops the views regarding the contributions of
diﬀerent pathomechanisms evolved, and the concept of RNA-
mediated pathogenesis, unifying most if not all TREDs, is
becoming more sound. The speciﬁc protein sequestration by
dsRNA repeat, which triggers the mechanism of RNA path-
ogenesis, was discussed here in more details. This is a sort of
protein ‘‘gain and loss’’ game in which numerous RNA and
protein players participate. Our ongoing research is focused on
the identiﬁcation and detailed characterization of all RNA
players in this game. We use RNA structure analysis and the
tools of genetics to answer the question of how the repeat
polymorphism in genes translates to RNA structure varieties
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